English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

1 Asst. Proff. Deptt of Respiratory Medicine, School of Medical Science and Research Greater Noida, UP, India 2 Senior Resident, PG Deptt. of Ophthalmology, S.N. Medical College Agra. UP, India 3 Asso. Proff. & Head, PG Deptt. of TB &Chest diseases, S.N. Medical College Agra. UP, India 4 Senior Resident, PG Deptt. of Medicine, S.N. Medical College Agra UP ,India *Corresponding Author Dr Anupriya Mehrotra Senior Resident, P.G. Department of Ophthalmology, Sarojini Naidu Medical College, Agra-282002 Uttar Pradesh, India Mobile: +9411684812 Email: dr.anupriya1989@gmail.com Abstract Objective: To study the Ocular side effect by chronic use of steroid in Chronic obstructive pulmonary disease (COPD) attending tertiary care center in north India Method: 500 COPD patients of age group 50 -90 years with minimum steroid exposure of 4 months and on inhaled corticosteroids were selected from TBCD and Ophthalmology department, S.N. Medical College and Hospital, Agra during the period of one year August 2017 to August 2018, a detailed clinical history, physical and ocular examination was done. Various investigations and diagnostic criteria were used during study. Average daily dose of inhaled corticosteroids was defined as low (1–250 μg), medium (251–500 μg), and high (501–1000 μg) using fluticasone propionate equivalents Result: Out of 500 COPD patients, of which 58 were dropouts. We identified 78 cataract and 24 glaucoma patients with a prevalence of 17.64 % and 5.42% respectively. We also observed a dose-response relationship with the highest prevalence of cataract (39.74%) and glaucoma (41.6%) at daily doses of 501– 1000 μg fluticasone propionate equivalents. Conclusion: Both cataract and glaucoma are associated with Chronic use of high dose inhaled corticosteroid in COPD patients, cataract being the more commoner one, judicious use of such medication can prevent these manifestations.

journal of medical science and clinical research

To Study the Ocular Side Effect by Chronic Use of Steroid in Chronic Obstructive Pulmonary Disease (COPD) Patients Attending Tertiary Care Centre in North India